Medifast, Inc. Announces Fourth Quarter and Full Year 2018 Financial Results

Medifast, Inc. reported financial results for the fourth quarter and full year ended December 31, 2018.

Revenue Increased 87% in the Fourth Quarter and 66% for the Full Year

Net Income Increased 114% in the Fourth Quarter and 101% for the Full Year

Company Introduces First Quarter and Fiscal Year 2019 Outlook

BALTIMORE, Feb. 26, 2019 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), a leading manufacturer and distributor of clinically proven, healthy living products and programs, today reported financial results for the fourth quarter and full year ended December 31, 2018.

(PRNewsfoto/Medifast, Inc.)

Fourth Quarter 2018 Highlights:

  • Revenue of $145.8 million, an increase of 87.0% year-over-year
  • Active earning Coaches of 24,100, an increase of 60.7% year-over-year
  • Net income of $15.7 million, an increase of 114.2% year-over-year
  • Earnings per diluted share ("EPS") of $1.30, an increase of 116.7% year-over-year

Full Year 2018 Highlights:

  • Revenue of $501.0 million, an increase of 66.1% year-over-year
  • Net income of $55.8 million, an increase of 101.3% year-over-year
  • EPS of $4.62, an increase of 101.7% year-over-year
  • Cash, cash equivalents, and investment securities of $101.0 million and debt-free
  • Returned $23.2 million to stockholders through payment of quarterly cash dividend
  • Repurchased $30 million of the Company's common stock

"We are very pleased with our strong finish to 2018," commented Dan Chard, Medifast's Chief Executive Officer. "We reached a significant corporate milestone generating over $500 million in annual revenue and profitability exceeded our expectations. Importantly, we achieved these results while accelerating the level of strategic investment to support our long-term growth plans to build our brand platform and operations as we continue to improve the scalability of our business. As we move forward with our strategic initiatives, both domestically and internationally, we believe we remain well positioned to deliver long-term sustainable growth and value for our shareholders as well as meaningful improvements to the lives of OPTAVIA clients across the country as they learn new healthy habits that make their lives better."

Fourth Quarter 2018 Results

For the fourth quarter of 2018, revenue increased 87.0% to $145.8 million from revenue of $78.0 million for the fourth quarter last year. OPTAVIA-branded products represented 72% of consumable units sold for the fourth quarter of 2018 compared to 51% for the fourth quarter of last year. The total number of active earning OPTAVIA Coaches for the fourth quarter of 2018 increased to 24,100, compared to 15,000 for the fourth quarter of 2017. The average revenue per active earning OPTAVIA Coach for the fourth quarter of 2018 increased 26.2% to $5,756 compared to $4,562 for the fourth quarter last year.

Gross profit for the fourth quarter of 2018 increased to $109.1 million from $59.1 million for the fourth quarter of 2017. The Company's gross profit as a percentage of revenue decreased 100 basis points to 74.8% from 75.8% for the fourth quarter last year. The decrease in gross margin percentage was driven by increased inventory reserves for a select group of products as well as higher freight costs to support year end customer demands.

Selling, general and administrative expenses ("SG&A") for the fourth quarter of 2018 increased $39.7 million to $89.3 million compared to $49.6 million for the fourth quarter of 2017, primarily as a result of higher OPTAVIA commissions expense, consulting costs related to information technology projects, and investments the Company is making in an upcoming International Leadership Advancement Trip ("ILAT") which is designed to reward qualifying business leaders with exclusive training and development opportunities. As previously disclosed, the ILAT expense was recorded in the third and fourth quarters of 2018 and is expected to drive strong growth in 2019. SG&A as a percentage of sales decreased 240 basis points to 61.2% of total revenue compared to 63.6% in the fourth quarter of 2017.

Operating income increased $10.3 million to $19.8 million from $9.5 million for the fourth quarter of 2018 primarily as a result of increased gross profit, partially offset by increased SG&A expenses. Operating income as a percentage of revenue increased 140 basis points to 13.6% compared to 12.2% in the fourth quarter of 2017.

The fourth quarter 2018 effective tax rate was 22.4%, compared to 25.4% for the fourth quarter of 2017. This decrease was primarily a result of the decrease in the Federal statutory rate pursuant to the Tax Cuts & Jobs Act rate of 14.0% offset by 2.1% due to the elimination of the Domestic Manufacturer Deduction, 5.0% due to a decrease in the windfall related to stock compensation and 3.0% due to a change in temporary differences resulting from the Tax Cuts & Jobs Act.

Net income for the fourth quarter of 2018 was $15.7 million, or $1.30 per diluted share, based on approximately 12.0 million shares outstanding. Fourth quarter 2017 net income was $7.3 million, or $0.60 per diluted share based on approximately 12.1 million shares outstanding.

Fiscal 2018 Results

For the fiscal year ended December 31, 2018, revenue increased 66.1% to $501.0 million compared to revenue of $301.6 million in 2017.

Net income for 2018 was $55.8 million, or $4.62 per diluted share based on approximately 12.1 million shares, compared to $27.7 million, or $2.29 per diluted share for the comparable period last year based on approximately 12.1 million shares outstanding.

Balance Sheet

The Company's balance sheet remains strong with stockholders' equity of $109.1 million and working capital of $85.2 million as of December 31, 2018. Cash, cash equivalents, and investment securities increased $2.2 million to $101.0 million as of December 31, 2018 compared to $98.8 million at December 31, 2017. The Company remains free of interest bearing debt. Inventory increased $19.6 million to $38.9 million as of December 31, 2018 compared to $19.3 million as the Company increased inventory levels to meet current and future customer demand.

The Company declared a quarterly cash dividend of $9.1 million, or $0.75 per share, during the fourth quarter of 2018.

Adoption of Accounting Standard Update 2014-09, Revenue from Contracts with Customers ("ASC 606"

As announced in the first quarter of 2018, the Company adopted ASC 606 on a modified retrospective basis. As a result, the Company did not restate financial information for the three months ended December 31, 2017. The results of ASU 606 primarily impact the Company's timing of revenue recognition for product shipments, as product revenue will be recognized upon customer receipt in lieu of at the time of shipment.

The following are the impacts to the financial results for the three months ended December 31, 2018 from the implementation of ASC 606. For the quarter ended December 31, 2018, revenue increased $3.1 million, or 2.2%, which resulted in increased gross profit of $2.4 million, or 2.2%. Gross profit as a percentage of revenue increased 10 basis points to 74.8% for quarter ended December 31, 2018. Income from operations increased $1.0 million, or 5.5%, resulting in increased net income and diluted earnings per share of $0.8 million, or $0.07 per share, respectively.

As of December 31, 2018, working capital decreased $2.3 million and stockholders' equity decreased $1.8 million as a result of the impact ASC 606.

Outlook

The Company expects first quarter revenue to be in the range of $150 million to $155 million and EPS to be in the range of $1.50 to $1.55. For the full year 2019, the Company expects revenue of $700 million to $720 million and EPS of $6.45 to $6.65. The full year 2019 earnings guidance assumes a 22.5% to 23.5% effective tax rate. The Company expects the 2019 cadence of spending to be similar to 2018 with its annual convention spend occurring in the third quarter of the year and the cost of a 2020 Leadership Advancement event to be incurred in the third and fourth quarters of the year. Based on capital investments in the Company's future growth, it expects capital expenditures in 2019 to be approximately $15.0 million or 2.0% of revenues.

Conference Call Information

The conference call is scheduled for today, Tuesday, February 26, 2019 at 4:30 p.m. ET. The call will be broadcast live over the Internet hosted at the Investor Relations section of Medifast's website at www.MedifastInc.com, and will be archived online through March 12, 2019. In addition, listeners may dial (855) 560-2579.

A telephonic playback will be available from 6:30 p.m. ET, February 26, 2019, through March 5, 2019. Participants can dial (877) 344-7529 to hear the playback and enter passcode 10128715.

About Medifast®:

Medifast (NYSE: MED) is a leading manufacturer and distributor of clinically proven, healthy living products and programs. The brand has been recommended by more than 20,000 doctors since its founding. Its integrated coach model leverages nearly 40 years of experience from medical, franchise, e-commerce, and direct selling channels. Medifast and its community of independent OPTAVIA Coaches embrace the future of wellness with a shared vision to offer the world lifelong transformation, one healthy habit at a time™. OPTAVIA® is represented by a community of OPTAVIA Coaches who teach Clients healthy habits, while offering support and guidance on their transformation journey. In 2018, Medifast announced it will expand into the Asia-Pacific markets of Hong Kong and Singapore in 2019 with its integrated coach model. Medifast is traded on the New York Stock Exchange and was named to Forbes' 100 Most Trustworthy Companies in America List in 2016 and 2017. For more information, visit www.MedifastInc.com or www.OPTAVIA.com.

MED-F

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Medifast believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Medifast's inability to attract and retain independent OPTAVIA Coaches and Members, stability in the pricing of print, TV and Direct Mail marketing initiatives affecting the cost to acquire customers, increases in competition, litigation, regulatory changes, and its planned growth into new domestic and international markets and new channels of distribution. Although Medifast believes that the expectations, statements, and assumptions reflected in these forward- looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

MEDIFAST, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(in thousands, except per share amounts & dividend data)

 
   

Three months ended December 31,

 

Year ended December 31,

   

2018

 

2017

 

2018

 

2017

                         

Revenue

 

$

145,844

 

$

78,007

 

$

501,003

 

$

301,563

Cost of sales

   

36,753

   

18,881

   

121,104

   

73,751

Gross profit

   

109,091

   

59,126

   

379,899

   

227,812

                         

Selling, general, and administrative

   

89,288

   

49,640

   

310,836

   

188,180

                         

Income from operations

   

19,803

   

9,486

   

69,063

   

39,632

                         

Other income (expense)

                       

Interest income, net

   

366

   

206

   

1,306

   

558

Other income (expense)

   

1

   

104

   

179

   

136

     

367

   

310

   

1,485

   

694

                         

Income from operations before income taxes

   

20,170

   

9,796

   

70,548

   

40,326

                         

Provision for income taxes

   

4,517

   

2,490

   

14,759

   

12,605

                         

Net income

 

$

15,653

 

$

7,306

 

$

55,789

 

$

27,721

                         

Earnings per share - basic

 

$

1.32

 

$

0.61

 

$

4.67

 

$

2.32

                         

Earnings per share - diluted

 

$

1.30

 

$

0.60

 

$

4.62

 

$

2.29

                         

Weighted average shares outstanding -

                       

Basic

   

11,894

   

11,941

   

11,947

   

11,924

Diluted

   

12,014

   

12,148

   

12,079

   

12,088

                         

Cash dividends declared per share

 

$

0.75

 

$

0.48

 

$

2.19

 

$

1.44

MEDIFAST, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(in thousands, except par value)

               
               
       

December 31, 2018

   

December 31, 2017

               

ASSETS

Current Assets

             

Cash and cash equivalents

   

$

81,364

 

$

75,077

Accounts receivable-net of doubtful accounts of $394 and $40 at

             

December 31, 2018 and 2017, respectively.

     

1,011

   

576

Inventory

     

38,888

   

19,328

Investment securities

     

19,670

   

23,757

Income taxes, prepaid

     

-

   

2,272

Prepaid expenses and other current assets

     

4,586

   

4,188

Total current assets

     

145,519

   

125,198

               

Property, plant and equipment - net

     

19,747

   

18,611

Other assets

     

1,183

   

2,120

Deferred tax assets

     

2,980

   

-

               
               

TOTAL ASSETS

   

$

169,429

 

$

145,929

               

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

             

Accounts payable and accrued expenses

   

$

60,323

 

$

37,140

Total current liabilities

     

60,323

   

37,140

               

Deferred tax liabilities

     

-

   

208

Total liabilities

     

60,323

   

37,348

               

Stockholders' Equity

             

Common stock, par value $.001 per share: 20,000 shares authorized;

             

12,117 and 12,103 issued and 11,868 and 11,971 outstanding

             

at December 31, 2018 and December 31, 2017, respectively

     

12

   

12

Additional paid-in capital

     

8,802

   

4,967

Accumulated other comprehensive loss

     

(173)

   

(160)

Retained earnings

     

131,344

   

103,762

Less: Treasury stock at cost, 193 shares at December 31, 2018

     

(30,879)

   

-

Total stockholders' equity

     

109,106

   

108,581

               

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

   

$

169,429

 

$

145,929

               

The impact of the adoption of the new revenue standard on the Company's Consolidated Statements of Income and Consolidated Balance Sheets was as follows (in thousands):

                                     
   

Three months ended December 31, 2018

 

Year ended December 31, 2018

   

As Reported

 

Balances without
adoption of ASC 606

 

Effect of Change

 

As Reported

 

Balances without
adoption of ASC 606

 

Effect of Change

                                     

Revenue

 

$

145,844

 

$

142,753

 

$

3,091

 

$

501,003

 

$

499,195

 

$

1,808

Cost of sales

   

36,753

   

36,046

   

(707)

   

121,104

   

120,590

   

(514)

Gross profit

   

109,091

   

106,707

   

2,384

   

379,899

   

378,605

   

1,294

                                     

Selling, general, and administrative

   

89,288

   

87,943

   

(1,345)

   

310,836

   

309,851

   

(985)

                                     

Income from operations

   

19,803

   

18,764

   

1,039

   

69,063

   

68,754

   

309

                                     

Other income (expense)

                                   

Interest income, net

   

366

   

366

   

-

   

1,306

   

1,306

   

-

Other income (expense)

   

1

   

1

   

-

   

179

   

179

   

-

     

367

   

367

   

-

   

1,485

   

1,485

   

-

                                     

Income from operations before income taxes

   

20,170

   

19,131

   

1,039

   

70,548

   

70,239

   

309

                                     

Provision for income taxes

   

4,517

   

4,300

   

(217)

   

14,759

   

14,696

   

(63)

                                     

Net income

 

$

15,653

 

$

14,831

 

$

822

 

$

55,789

 

$

55,543

 

$

246

                                     

Earnings per share - basic

 

$

1.32

 

$

1.25

 

$

0.07

 

$

4.67

 

$

4.65

 

$

0.02

                                     

Earnings per share - diluted

 

$

1.30

 

$

1.23

 

$

0.07

 

$

4.62

 

$

4.60

 

$

0.02

                                     

Weighted average shares outstanding -

                                   

Basic

   

11,894

   

11,894

         

11,947

   

11,947

     

Diluted

   

12,014

   

12,014

         

12,079

   

12,079

     
                                     
                                     
                                     
                                     
                                     
   

December 31, 2018

                 
   

As Reported

 

Balances without
adoption of ASC 606

 

Effect of Change

                 
                                     

ASSETS

                                   

Accounts receivable, net

 

$

1,011

 

$

81

 

$

930

                 

Inventory

   

38,888

   

38,421

   

467

                 

Prepaid expenses and other current assets

   

4,586

   

4,509

   

77

                 

Deferred tax assets

   

2,980

   

2,498

   

482

                 
                                     

LIABILITIES

                                   

Accounts payable and accrued expenses

   

60,323

   

56,595

   

3,728

                 
                                     

STOCKHOLDERS' EQUITY

                                   

Retained earnings

   

131,344

   

133,116

   

(1,772)

                 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/medifast-inc-announces-fourth-quarter-and-full-year-2018-financial-results-300802664.html

SOURCE Medifast, Inc.


Company Codes: NYSE:MED

MORE ON THIS TOPIC